NeoStem, Inc. — Form 10-Q Summary
Filing and period: The supplied filing is NeoStem, Inc.’s unaudited 10-Q for the quarter ended March 31, 2012—not a Lisata Therapeutics filing for 2011 Q1, as the request metadata indicates.
Business context
NeoStem operated U.S. cell therapy and Chinese pharmaceutical manufacturing businesses. Effective March 31, 2012, it classified its China regenerative medicine operations as discontinued. The company was also pursuing a sale of its 51% interest in Erye, its Chinese pharmaceutical manufacturer.
Financial performance and liquidity
| Metric | Q1 2012 | Q1 2011 |
|---|---|---|
| Revenue | $22.06 million | $19.59 million |
| Gross profit / margin | $5.74 million / 26.0% | $5.31 million / 27.1% |
| Operating loss | $6.43 million | $7.08 million |
| Net loss | $9.21 million | $9.70 million |
| Net loss attributable to common shareholders | $9.46 million; $0.08 per share | $10.36 million; $0.14 per share |
| Operating cash flow | $2.11 million provided | $10.20 million used |
- Revenue rose approximately 12.6%. U.S. cell therapy revenue increased 160% to $3.77 million, largely from PCT clinical manufacturing and process-development services. China pharmaceutical revenue was nearly flat at $18.28 million.
- Gross profit increased, but gross margin declined. Operating expenses edged down 2% to $12.17 million; reported share-based compensation was $2.47 million.
- Cash and cash equivalents were $21.77 million at quarter-end, up from $12.64 million at year-end. Working capital was $5.84 million. Current assets were $52.98 million and current liabilities $47.14 million.
- Operating cash flow turned positive, but included a $10.23 million contribution from accounts payable, accrued expenses and other current liabilities. Investing activities used $0.11 million; financing activities provided $7.19 million, including equity proceeds.
- Quarter-end bank loans were $15.81 million; notes payable totaled approximately $0.31 million and mortgages $3.58 million. The company also reported $21.29 million due to Erye’s 49% shareholder, EET, related to dividends loaned back to Erye.
- Of cash and short-term investments held by Erye, $14.77 million was not available for domestic operations unless repatriated. Separately, approximately $2.66 million of Erye cash was frozen in connection with litigation.
Material changes and unusual items
- Continuing-operations net loss improved to $7.48 million from $8.77 million. Total net loss was $9.21 million, including $1.72 million from discontinued operations versus $0.93 million a year earlier.
- The company recorded a $1.14 million loss on exiting its China regenerative medicine segment. It stated it expected no continuing involvement in that business.
- Common shares outstanding increased from 109.33 million at December 31, 2011 to 129.89 million at March 31, 2012. February and March equity financings raised approximately $7.55 million net; a further $0.74 million net was raised in April through the offering over-allotment.
- The filing reports a material weakness in Erye’s accounting controls, including deficiencies in segregation of duties, asset records, tax expertise and transaction audit trails. Management concluded disclosure controls were not effective as of quarter-end.
Outlook, risks and contingencies
- Management anticipated monetizing its Erye interest by the end of 2012, but gave no assurance a sale would occur or provide material proceeds. The sale process faced EET’s right of first refusal, a related-party loan repayment issue, Chinese regulatory approvals and market and operating challenges.
- The company expected substantial additional funding needs. Its AMR-001 Phase 2 trial was estimated to cost approximately $14 million over the first two years and up to $18 million over five years, including manufacturing. The company said it may seek equity or debt financing, asset-sale proceeds, warrant or option exercises, and grants; availability of financing was uncertain and further equity could dilute shareholders.
- China risks include government-driven drug price reductions, proposed limits on antibiotic use, concentration in antibiotic products and suppliers, and restrictions on transferring subsidiary earnings. The company reported that more than 70% of Erye’s manufactured drugs were on China’s essential drug list.
- In a Welman dispute, a Chinese court had frozen approximately $2.66 million of Erye deposits. A separate preliminary injunction concerning product package inserts remained in effect while Erye sought reconsideration. The filing describes other litigation developments; the ultimate financial exposure is not clearly quantified.
- NeoStem disclosed that Chinese regulatory approvals and registrations relating to the legal holding of its Erye interest remained outstanding. Remediation could involve tax liabilities and penalties, which the company could not reasonably assess at quarter-end.
- As subsequent events, the company reported a May 2012 private placement of $1.3 million gross and an April compensation program under which participating officers could receive options in lieu of salary.
Important facts for investors to verify
- Whether Erye is sold, the proceeds and timing, and the status of EET’s rights and the approximately $21.3 million related-party balance.
- Cash actually available to the U.S. business after accounting for Erye-held funds, frozen deposits and restricted cash.
- Whether the company can fund the AMR-001 trial and other operations without further dilutive financing.
- Progress in remediating the Erye accounting-control material weakness and Chinese regulatory deficiencies.
- Developments in the Welman litigation and any resulting effect on Erye’s liquidity or operations.